Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aticaprant Long-term Safety in MDD (Open-label Extension)
CTR20233277Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aticaprant in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Oct 2023; status: terminated.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20233277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233277.